Former OrphoMed CEO Gary Phillips (Anaveon)
A Takeda-backed GI and pain biotech quietly shutters
A biotech aiming to treat various gastrointestinal ailments, as well as develop a non-opiate pain med, quietly shut down last year after failing to find …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
